Trial · NCT07208539
AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.
NCT07208539, Phase 2, Not yet recruiting, Shanghai Zhongshan Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer. Trials, record NCT07208539. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07208539
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.
- NCT number
- NCT07208539
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 77 participants, estimated
- Lead sponsor
- Shanghai Zhongshan Hospital
- Conditions
- Pancreatic Cancer
- Interventions
- Treatment: AG & anti-PD-L1 + FOLFIRINOX & anti-PD-L1
- First posted
- 2025-10-06
- Last updated
- 2025-10-06
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 18-month overall survival (OS) rate | From the date of first enrollment to 18 months later. | To test whether the 18-month OS rate of patients with borderline resectable or locally advanced pancreatic cancer treated with the sequential therapy was comparable to that of the historical data of the general adult population. |
| Secondary | Surgical conversion rate | From the date of first enrollment to the date of completion of follow-up of the last patient, up to 30 months. | The surgical conversion rate refers to the process of transforming an initially inoperable tumor into one that can be removed through a pre-defined treatment plan. The conversion rate is the proportion of subjects who successfully underwent the conversion treatment among all subjects who received such treatment. |
| Secondary | Overall survival rate (OS) | From the date of first enrollment to the date of completion of follow-up of the last patient, up to 30 months. | |
| Secondary | Event-free survival (EFS) | From the date of first enrollment to the date of completion of follow-up of the last patient, up to 30 months. | Survival time from the first enrollment to the date of first documented progression or the date of death. |
| Secondary | R0 resection rate | From the date of first enrollment to the date of completion of follow-up of the last patient, up to 30 months. | The R0 resection rate is defined as the proportion of subjects who were assessed as having achieved R0 resection (complete tumor removal, with no cancer cells found at the microscopic margin, no cancer cells remaining either macroscopically or under the microscope, and the lesion was completely removed) after the surgery. |
| Secondary | R1 resection rate | From the date of first enrollment to the date of completion of follow-up of the last patient, up to 30 months. | The R1 resection rate is defined as the proportion of subjects who were assessed as having undergone R1 resection (microscopic residual, all large lesions were removed, and there were cancer cells at the microscopic margin) after the surgery. |
| Secondary | Objective response rate (ORR) | From the date of first enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months. | ORR is defined as the percentage of patients who achieve complete response (CR) or partial response (PR) based on the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. |
| Secondary | Toxicity and side effects and tolerability assessment | From the date of first therapy administration to within 90 days, up to 30 months. | Safety and tolerance will be evaluated by incidence, severity and outcomes of adverse events (AEs) and categorized by severity in accordance with the NCI CTCAE Version 5.0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07208539
GET https://conductscience.org/api/trials/v1/NCT07208539/registered